more food for thought on this point: "Shares in high-yielding telecom company Windstream Holdings Inc. (WIN) have surged 21% to $12.72 Tuesday on plans to spin off certain network assets into a real-estate investment trust." (Barron's online, 29 July 2014)
Nice move up today on earnings. Google the "MYCC Earnings Call Transcript Q2" and read the analyst questions and somewhat coy replies regarding a REIT conversion. Wouldn't that be about a 30% upward catalyst for this stock? Almost all REIT conversions show a substantial pop, rewarding those who were on board early.
Given today's rise, consider selling some covered calls at 115 or so (Jan 2015 or even 2016 if you can hold that long). The premium is quite high, that way you get some downside protection. You have to decide if 115 or 120 or ?? is enough upside for you.
When PCYC was 135-140 I sold covered calls at 190-200 (January 2016, surprisingly large premiums), that has helped cushion me with regard to this (temporary in my opinion) downturn.
sorry, I wanted to rate you thumbs up and I hit the wrong button -- always appreciate a note on a ratings change
I like the stock, but is this secondary offering consistent with a "breakout play"?
"Eros International Plc Launches Follow-On Equity Offering", posted under news for this company by yahoo
As someone who writes covered calls on 33-40% of his portfolio, an observation: The way the calls I sold for CHK are now listed, I will have to give up some of my SSE shares if they are called. This would be easy for some other investors to overlook. I added to my SSE position yesterday (glad I did with the price action) to create round lots. However, if I liquidate this position I would in theory be left with a naked (partially naked) call.
Just a heads up for those who have sold CHK calls in the past.
SSE continues to run up. I bought a few more shares Tuesday to have a round lot (400 total). Seeking alpha (and let's admit this is a very flawed authority) doesn't have anything positive to say about SSE. So what is driving the price so strongly higher the last few days?
you will have more credibility on this board if you state your reasoning (think of the many vapid posts about "this stock should be $XX" you read on other boards)
This was reported today and would seem to be a good driver of future growth. Au contraire, anyone?
Very disappointing performance in absence of bad news (my average price is about 3.9); shorts are in here? I'm worried I'm going to take a 50% haircut before things *might* get better
Last weekend, Barron's recommended taking profits:
Shares of Ambac Financial Group have surged since we wrote about a potential windfall for the bond insurer that went bankrupt in the midst of the financial crisis in late 2010. In our story ("Ambac: Where a Smaller Portfolio Means a Bigger Stock Price," Dec. 23, 2013), analysts estimated that the guarantor of payments on mortgage- and asset-backed securities might be able to settle claims against it for $5 billion or less, well below the $6.6 billion set aside for them. Aided by a healthier mortgage market that reduced foreclosures and the possibility of payments from big banks to settle allegations about faulty mortgage originations, Ambac (ticker: AMBC) was in better shape than it appeared.
The possibility of $1.6 billion or more in found money for a small-cap insurer helped push the stock as high as $34.68 in early March from $20.63 at the time of our story. It's since settled back to around $28—still a 36% rise versus the S&P 500's 4.4% gain—as some of the enthusiasm about the mortgage markets and legal settlements has waned.
"We need more evidence of progress" of recoveries from lawsuits and reduction of obligations, to support higher equity values, says Mark Palmer, an analyst for New York brokerage BTIG, who has shifted from bullish to neutral. Similarly, Brian Charles, a special-situations analyst at broker R.W. Pressprich, on March 10 slapped a sell advisory on the stock.
There are still bulls who are confident about the payments' arrival. Andrew Gadlin, an analyst with broker Odeon Capital Group, maintains a $45 price target. "I still believe there's a possible $2 billion windfall based on incremental litigation recoveries," he says. Our advice? Take the 36% gain and then wait to see if you can get another shot later below $20.
Excellent find Joe. Nothing beats solid peer reviewed literature. This article will be the "gold standard" for many scientists and clinicians. There is nothing like this out there for Ibrutinib competitors.
I noticed also, and today is another high; what's the driver in your opinion? No new news that I see, although is a favorite holding of some funds.